Three cardiac biomarkers and their efficacy: A review

Abstract

Objectives: This study belongs to the overview of three versatile cardiac biomarkers for specific diagnosis and prognosis in cardiac patients.
 Methods: A search performed in different search sites such as Web of Science, Pub Med, and Google scholar searches for relevant studies from 2015 to 2022. Search names included were “heart disease,” “cardiac troponin,” “acute coronary disease,” “coronary artery disease,” “new biomarker,” “non–ST-elevation acute coronary syndrome,” etc. Studies were included if they were prospective, retrospective, randomized controlled trials or reviews.
 Findings: Troponin I &T along with CPK-MB can increase the diagnostic sensitivity and specificity when used collectively in the diagnosis of Myocardial infarction either acute or chronic conditions. These cardiac versatile biomarkers can diagnose re-infarct also with serial testing. Whereas sensitivity and specificity of Troponins I &T ranges from 84 to 96 and 80 to 95% respectively. When all three cardiac markers were combined, sensitivity and specificity will reach up to approximately 100%.
 Novelty/ Improvement: This article provides the best available three versatile specific cardiac biomarkers in the diagnosis of myocardial infarction and reinfarction with about 100% accuracy.
 Keywords: Cardiovascular Disease (CVD), Myocardial Infarction (MI), Acute Myocardial Infarction (AMI), Lactate Dehydrogenase (LDH), Creatine Kinase (CK), Heart type fatty acid binding protein (H-FABP).